These findings highlight the potentially pleiotropic benefits of BYL719 in the treatment of proliferative glomerulonephritis and reveal a role for aberrant PI3K activation as a driver of podocyte hyperplasia (21). The gene discussed is PIK3CA; the disease is proliferative glomerulonephritis.